{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Acetate+%28AA%29", "query": { "intervention": "Abiraterone Acetate (AA)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+Acetate+%28AA%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T03:43:39.267Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT02123758", "title": "A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms", "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "JNJ-56021927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 57, "start_date": "2014-07-09", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02123758" }, { "nct_id": "NCT02025010", "title": "Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2014-01-27", "completion_date": "2025-04-07", "has_results": true, "last_update_posted_date": "2025-04-15", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 8, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02025010" }, { "nct_id": "NCT06650579", "title": "REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Prostate Carcinoma", "Stage III Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography Angiography", "type": "PROCEDURE" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2025-01-31", "completion_date": "2029-07-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06650579" }, { "nct_id": "NCT04887506", "title": "TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Metastatic Castration-sensitive Prostate Cancer", "Metastatic Prostate Cancer" ], "interventions": [ { "name": "TAVT-45", "type": "DRUG" }, { "name": "Zytiga", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tavanta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 107, "start_date": "2021-05-05", "completion_date": "2022-10-20", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 13, "location_summary": "Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887506" }, { "nct_id": "NCT04577833", "title": "A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Abiraterone Acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2020-11-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 1, "location_summary": "West Valley City, Utah", "locations": [ { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577833" }, { "nct_id": "NCT06329830", "title": "177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer", "Castration-resistant Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "Niraparib abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baptist Health South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": "2024-10", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06329830" }, { "nct_id": "NCT02257736", "title": "An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 982, "start_date": "2014-11-26", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 46, "location_summary": "Phoenix, Arizona • La Mesa, California • Los Angeles, California + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257736" }, { "nct_id": "NCT06421935", "title": "M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M9466", "type": "DRUG" }, { "name": "Tuvusertib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-08-07", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06421935" }, { "nct_id": "NCT01088529", "title": "Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "LHRHa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cougar Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 66, "start_date": "2009-12", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-05-15", "last_synced_at": "2026-10-01T03:43:39.267Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088529" } ] }